The coordinated buying by multiple fund types, especially Elliott's activist push, suggests a re-rating catalyst may be approaching. Watch for upcoming earnings, FDA updates on DefenCath, or potential strategic moves. The 45-day filing lag means positions may have been adjusted since December; any 13D amendment filing by Elliott would be an immediate bullish trigger.
CRMD drugs
CRMD drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jun 12 $8.74entry
- T+1 · 5mo ago −1.72%α −3.48% · $8.59
- T+5 · 5mo ago −0.80%α −1.47% · $8.67
- T+20 · 4mo ago −3.89%α −5.67% · $8.40
- T+60 · 2mo ago −6.41%α −9.67% · $8.18
How similar events traded
Executive Summary
A strong institutional cluster formed in CRMD during Q4 2024, with 8 buyers (net +$14.6M) overwhelming 3 sellers (net -$5.8M). The accumulation is led by activist Elliott Management, which added 85% to now hold $23.3M, alongside participation from quant fund D.E. Shaw and mega-passive UBS. This signals growing conviction in CorMedix's commercial prospects ahead of potential catalysts.
Key Financial Metrics
Institutional Positions
Net institutional flow: $8.8M
▲ Buyers (8)
| Institution | Action | Change | Position Value | Value Δ |
|---|---|---|---|---|
| Elliott Management | ADD | +85.1% | $23.3M | $10.7M |
| D.E. Shaw | ADD | +39.1% | $3.6M | $1.0M |
| UBS | DOUBLED | +861.3% | $3.1M | $2.8M |
▼ Sellers (3)
| Institution | Action | Change | Prev Value | Value Δ |
|---|---|---|---|---|
| Voya Investment Management | NEAR_EXIT | -97.5% | $5.8M | -$5.6M |
Key Facts
- 8 institutional buyers vs 3 sellers in Q4 2024
- Elliott Management (activist) increased stake by 85.1% to 2.87M shares ($23.3M)
- UBS more than doubled its position (+861%), now holding $3.1M
- D.E. Shaw added 39.1%, now $3.6M
- Net institutional inflow of approximately $8.8M
- Voya Investment Management nearly exited (-97.5%), selling $5.6M
Financial Impact
Net institutional buying of $8.8M in Q4 2024, with $14.6M added by buyers and $5.8M sold by sellers. The cluster represents new capital deployment into CRMD at a time of high analyst bullishness (92% buy ratings).
Risk Factors
- 13F data is 45+ days stale; positions may have been partially unwound
- Small-cap biotech volatility could reverse gains quickly
- Voya's near-exit signals some institutional skepticism
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 institutional 13F filing from SEC EDGAR.
| Document | Accession Number |
|---|---|
| INST-CLUSTER Data (Synthetic) | inst-cluster-CRMD-2024-Q4 |
Track record
21 reports on CRMD
9 of 9 bullish or bearish reports moved the stock their way by T+5. Best: +34.13% at T+60 after the Mar 5, 2026 report. 10 of 11 went positive at some point.
Filters
- Nov 12, 20264d ago Press Release Bearish 5/10 Entry $4.84 settles Nov 19
- Nov 10, 20266d ago DEFA14A Neutral 6/10 Entry $5.30 settles Nov 18
- Nov 10, 20266d ago 8-K Bullish 7/10 Entry $5.30 settles Nov 18
- Nov 9, 20267d ago DEFA14A Neutral 6/10 Entry $5.47 to $4.82 ▼ −11.88% −10.19% vs SPY
- Nov 9, 20267d ago 8-K Neutral 6/10 Entry $5.47 to $4.82 ▼ −11.88% −10.19% vs SPY
- Nov 2, 202614d ago 8-K Neutral 5/10 No price data
- Nov 2, 202614d ago Press Release Neutral 4/10 Entry $5.39 to $5.47 ▲ +1.48% +1.41% vs SPY
- Oct 19, 202628d ago 8-K Bullish 7/10 Entry $7.38 to $7.94 ▲ +7.59% +7.73% vs SPY
- Oct 19, 202628d ago Press Release Bullish 7/10 Entry $7.38 to $8.03 ▲ +8.74% +8.88% vs SPY
- Aug 13, 202613w ago 8-K Neutral 5/10 No price data
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers